Article
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma.
Journal of experimental & clinical cancer research : CR - 19 Apr 2022
Loria Rossella, Laquintana Valentina, Scalera Stefano, Fraioli Rocco, Caprara Valentina, Falcone Italia, Bazzichetto Chiara, Di Martile Marta, Rosanò Laura, Del Bufalo Donatella, Bossi Gianluca, Sperduti Isabella, Terrenato Irene, Visca Paolo, Soddu Silvia, Milella Michele, Ciliberto Gennaro, Falcioni Rita, Ferraresi Virginia, Bon Giulia
Abstract excerpt
BACKGROUND: Despite the promise of dual BRAF/MEK inhibition as a therapy for BRAF-mutant (BRAF-mut) melanoma, heterogeneous responses have been observed in patients, thus predictors of benefit from therapy are needed. We have previously identified semaphorin 6A (SEMA6A) as a BRAF-mut-associated protein involved in actin cytoskeleton remodeling. The purpose of the present study is to dissect the role of SEMA6A in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
